Different mechanisms are involved in the antibody mediated inhibition of ligand binding to the urokinase receptor: A study based on biosensor technology

Journal of Immunological Methods

Volumn 222, Issue 1-2, 1999, Pages 125-133

  List, Karin ^a   Høyer Hansen, Gunilla ^a   Rønne, Ebbe ^a   Danø, Keld ^a   Behrendt, Niels ^a  

^a FINSEN LABORATORY   (Denmark)

Author keywords

Competitive noncompetitive inhibition; Monoclonal antibody; Real time biomolecular interaction analysis (BIA); Urokinase (EC 3.4.21.73); Urokinase plasminogen activator receptor

Indexed keywords

UROKINASE RECEPTOR;

ANIMAL CELL; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BIOSENSOR; CANCER; CANCER INVASION; CROSS LINKING; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOSENSING TECHNIQUES; CHO CELLS; CRICETINAE; HUMANS; IODINE RADIOISOTOPES; LIGANDS; PEPTIDE FRAGMENTS; RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS; SOLUBILITY; TRANSFECTION; URINARY PLASMINOGEN ACTIVATOR;

ANIMALIA; BIA;

EID: 0032955836     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(98)00189-6     Document Type: Article

References (33)

1. Andreasen P.A., Kjøller L., Christensen L., Duffy M.J. The urokinase-type plasminogen activator system in cancer metastasis - a review. Int. J. Cancer. 72:1997;1.
2. Behrendt N., Stephens R.W. The urokinase receptor. Fibrinolysis and Proteolysis. 12:1998;. In press.
3. Behrendt N., Ploug M., Rønne E., Høyer-Hansen G., Danø K. Cellular receptor for urokinase-type plasminogen activator: protein structure. Methods in Enzymology. 233:1993;207-222.
4. Behrendt N., Rønne E., Danø K. Binding of the urokinase-type plasminogen activator to its cell surface receptor is inhibited by low doses of suramin. J. Biol. Chem. 268:1993;5985.
5. Behrendt N., Rønne E., Danø K. Domain interplay in the urokinase receptor - requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites in distinct receptor domains. J. Biol. Chem. 271:1996;22885.
6. Blasi F., Conese M., Møller L.B., Pedersen N., Cavallaro U., Cubellis M.V., Fazioli F., Hernandez-Marrero L., Limongi P., Munoz-Canoves P., Resnati M., Riittinen L., Sidenius N., Soravia E., Soria M.R., Stoppelli M.P., Talarico D., Teesalu T., Valcamonica S. The urokinase receptor: structure, regulation and inhibitor-mediated internalization. Fibrinolysis. 8:1994;182.
7. Crowley C.W., Cohen R.L., Lucas B.K., Liu G., Shuman M.A., Levinson A.D. Prevention of metastasis by inhibition of the urokinase receptor. Proc. Natl. Acad. Sci. USA. 90:1993;5021.
8. Danø K., Andreasen P.A., Grøndahl-Hansen J., Kristensen P., Nielsen L.S., Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res. 44:1985;139.
9. Danø K., Behrendt N., Brünner N., Ellis V., Ploug M., Pyke C. The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis. 8:1994;189.
10. Ellis V., Scully M.F., Kakkar V.V. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J. Biol. Chem. 264:1989;2185.
11. Ellis V., Behrendt N., Danø K. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J. Biol. Chem. 266:1991;12752.
12. Goodson R.J., Doyle M.V., Kaufman S.E., Rosenberg S. High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc. Natl. Acad. Sci. USA. 91:1994;7129.
13. Grøndahl-Hansen J., Ralfkiær E., Kirkeby L.T., Kristensen P., Lund L.R., Danø K. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am. J. Pathol. 138:1991;111.
14. Kallee E., Eiestert U., Wahl R. Inhibitory and disruptive effects of some antirheumatics on antigen-antibody complexes. Eur. J. Clin. Chem. Biochem. 33:1995;711.
15. Karlsson R., Ståhlberg R. Surface plasmon resonance detection and multispot sensing for direct monitoring of interactions involving low-molecular-weight analytes and for determination of low affinities. Anal. Biochem. 228:1995;274.
16. Karlsson R., Michaelsson A., Mattsson L. Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. J. Immunol. Meth. 145:1991;229.
17. Kobayashi H., Gotoh J., Fujie M., Shinohara H., Moniwa N. Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model. Int. J. Cancer. 57:1994;727.
18. Koretz K., Müller P., Schwartz-Albiez R. Plasminogen activators and plasminogen activator inhibitors in human colorectal carcinoma tissues are not expressed by the tumour cells. Eur. J. Cancer A. 29:1993;1184.
19. McNally A.J., Motter K., Jordan F. A library of monoclonal antibodies to Escherichia coli K-12 pyrovate dehydrogenase complex. J. Biol. Chem. 270:1995;19736.
20. Min H.Y., Semnani R., Mizukami I.F., Watt K., Todd R.F., Liu D.Y. cDNA for Mo3, a monocyte activation antigen, encodes the human receptor for urokinase plasminogen activator. J. Immunol. 148:1992;3636.
21. Min H.Y., Doyle L.V., Vitt C.R., Zandonella C.L., Stratton-Thomas J.R., Shuman M.A., Rosenberg S. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res. 56:1996;2428.
22. r receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification. J. Biol. Chem. 263:1988;2358.
23. Ploug M., Ellis V., Danø K. Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor. Biochemistry. 33:1994;8991.
24. Ploug M., Østergaard S., Hansen L.B. L, Holm A., Danø K. Photoaffinity labelling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation. Biochemistry. 37:1998;3612.
25. Pyke C., Kristensen P., Ralfkiær E., Grøndahl-Hansen J., Eriksen J., Blasi F., Danø K. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am. J. Pathol. 138:1991;1059.
26. Pyke C., Græm N., Ralfkiær E., Rønne E., Høyer-Hansen G., Brünner N., Danø K. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res. 53:1993;1911.
27. Remy M.H., Frobert Y., Grassi J. Characterization of monoclonal antibodies that strongly inhibit Electrophorus electricus acetylcholinesterase. Eur. J. Biochem. 231:1995;651.
28. 2-terminal domain of the urokinase receptor. FEBS Lett. 288:1991;233.
29. Rønne E., Høyer-Hansen G., Brünner N., Pedersen H., Rank F., Osborne C.K., Clark G.M., Danø K., Grøndahl-Hansen J. The urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Research and Treatment. 33:1995;199.
30. Shulman M., Wilde C.D., Köhler G. A better cell line for making hybridomas secreting specific antibodies. Nature. 276:1978;269.
31. Stahl A., Mueller B.M. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res. 54:1994;3066.
32. Stoppelli M.P., Corti A., Soffientini A., Cassani G., Blasi F., Assoian K. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase activator to a specific receptor on U937 monocytes. Proc. Natl. Acad. Sci. USA. 82:1985;4939.
33. Wei Y., Waltz D.A., Rao N., Drummond R.J., Rosenberg S., Chapman H.A. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J. Biol. Chem. 269:1994;32380.